Wealthcare Advisory Partners LLC Sells 1,975 Shares of Amgen Inc. $AMGN

Wealthcare Advisory Partners LLC lessened its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 11.4% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 15,360 shares of the medical research company’s stock after selling 1,975 shares during the quarter. Wealthcare Advisory Partners LLC’s holdings in Amgen were worth $5,562,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in the stock. Anfield Capital Management LLC boosted its holdings in Amgen by 1,000.0% in the fourth quarter. Anfield Capital Management LLC now owns 77 shares of the medical research company’s stock worth $25,000 after purchasing an additional 70 shares during the last quarter. Dogwood Wealth Management LLC raised its stake in Amgen by 275.0% during the 4th quarter. Dogwood Wealth Management LLC now owns 75 shares of the medical research company’s stock valued at $25,000 after buying an additional 55 shares during the last quarter. Tower View Wealth Management LLC raised its stake in Amgen by 331.6% during the 1st quarter. Tower View Wealth Management LLC now owns 82 shares of the medical research company’s stock valued at $29,000 after buying an additional 63 shares during the last quarter. Manning & Napier Advisors LLC lifted its holdings in shares of Amgen by 49.2% during the 4th quarter. Manning & Napier Advisors LLC now owns 97 shares of the medical research company’s stock valued at $32,000 after buying an additional 32 shares during the period. Finally, Ares Financial Consulting LLC bought a new position in shares of Amgen during the 4th quarter valued at $34,000. 76.50% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Amgen

In other news, SVP Nancy A. Grygiel sold 2,970 shares of the company’s stock in a transaction dated Thursday, August 6th. The stock was sold at an average price of $402.16, for a total value of $1,194,415.20. Following the completion of the transaction, the senior vice president owned 7,340 shares of the company’s stock, valued at $2,951,854.40. This represents a 28.81% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. 0.85% of the stock is currently owned by company insiders.

Amgen Stock Performance

Shares of NASDAQ AMGN opened at $414.30 on Wednesday. The stock has a market cap of $223.98 billion, a PE ratio of 25.75, a price-to-earnings-growth ratio of 3.88 and a beta of 0.41. Amgen Inc. has a 1 year low of $269.77 and a 1 year high of $421.79. The firm has a fifty day moving average price of $366.26 and a 200-day moving average price of $357.53. The company has a debt-to-equity ratio of 4.44, a current ratio of 1.37 and a quick ratio of 1.13.

Amgen (NASDAQ:AMGN) last released its earnings results on Tuesday, August 4th. The medical research company reported $6.29 earnings per share for the quarter, beating analysts’ consensus estimates of $5.62 by $0.67. The company had revenue of $10.05 billion for the quarter, compared to analysts’ expectations of $9.43 billion. Amgen had a net margin of 22.95% and a return on equity of 124.14%. Amgen’s revenue for the quarter was up 9.5% on a year-over-year basis. During the same quarter in the previous year, the company earned $6.02 EPS. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. Equities analysts anticipate that Amgen Inc. will post 22.78 earnings per share for the current fiscal year.

Amgen Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, September 11th. Stockholders of record on Friday, August 21st will be given a $2.52 dividend. This represents a $10.08 annualized dividend and a dividend yield of 2.4%. The ex-dividend date is Friday, August 21st. Amgen’s payout ratio is presently 62.65%.

Wall Street Analyst Weigh In

Several analysts recently commented on AMGN shares. Robert W. Baird lifted their price objective on Amgen from $215.00 to $230.00 and gave the stock an “underperform” rating in a report on Wednesday, August 5th. TD Cowen increased their target price on Amgen from $420.00 to $452.00 and gave the company a “buy” rating in a report on Wednesday, August 5th. Scotiabank raised their target price on Amgen from $385.00 to $450.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 5th. Mizuho boosted their price target on Amgen from $295.00 to $303.00 and gave the company a “neutral” rating in a research note on Tuesday, June 16th. Finally, Bank of America upped their price target on shares of Amgen from $312.00 to $317.00 and gave the company an “underperform” rating in a research report on Wednesday, August 5th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, fifteen have given a Hold rating and three have assigned a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $371.68.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.